Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Cytokine Release Syndrome 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Neurilemmoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Burkitt Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cyclophosphamide 3ruxolitinib 2fludarabine phosphate 2fludarabine 2Methotrexate 2thymoglobulin 1siltuximab 1duvelisib 1cc-486 1calaspargase pegol 1blinatumomab 1Whole-Body Irradiation 1Valganciclovir 1Transplantation 1Thiotepa 1Therapeutics 1Thalidomide 1Tacrolimus 1Radiotherapy 1Prednisone 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Mesna 1Melphalan 1Interleukin-6 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Ganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Large Granular Lymphocytic × siltuximab × 1 year × Clear all
NCT05316116 2026-02-05

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Terminated
6 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡